This site uses cookies. By accepting cookies you can optimise your browsing experience. Read more.
Germany: BioNTech and Pfizer announce '90 percent effective' COVID vaccine01:34

Germany: BioNTech and Pfizer announce '90 percent effective' COVID vaccine

Germany, Mainz
November 9, 2020 at 17:52 GMT +00:00 · Published

German company BioNTech and its American associate Pfizer announced on Monday that their experimental coronavirus vaccine was more than "90 percent effective" against COVID-19 infections.

Footage show the BioNTech offices in Mainz on Monday.

"I am happy to share with you that Pfizer and our collaborator, BioNTech, announced positive efficacy results from our Phase three, late-stage study of our potential COVID-19 vaccine. The vaccine candidate was found to be more than 90 percent effective in preventing COVID-19 in participants without evidence of prior SARS-CoV-Two infection in the first interim efficacy analysis," explained Pfizer chairman and CEO Albert Bourla in a statement.

"This means we are one step closer to potentially providing people around the world with a much-needed breakthrough to help bring an end to this global pandemic," Bourla added.

The two pharmaceutical companies said they are planning to produce up to 50 million vaccine doses in 2020 and up to one point three billion doses in 2021, pending extensive research and approval by the US Food and Drug Administration (FDA).

Germany: BioNTech and Pfizer announce '90 percent effective' COVID vaccine01:34
No Account? Sign up!
Top downloads in last 24 hours
Show more
Description

German company BioNTech and its American associate Pfizer announced on Monday that their experimental coronavirus vaccine was more than "90 percent effective" against COVID-19 infections.

Footage show the BioNTech offices in Mainz on Monday.

"I am happy to share with you that Pfizer and our collaborator, BioNTech, announced positive efficacy results from our Phase three, late-stage study of our potential COVID-19 vaccine. The vaccine candidate was found to be more than 90 percent effective in preventing COVID-19 in participants without evidence of prior SARS-CoV-Two infection in the first interim efficacy analysis," explained Pfizer chairman and CEO Albert Bourla in a statement.

"This means we are one step closer to potentially providing people around the world with a much-needed breakthrough to help bring an end to this global pandemic," Bourla added.

The two pharmaceutical companies said they are planning to produce up to 50 million vaccine doses in 2020 and up to one point three billion doses in 2021, pending extensive research and approval by the US Food and Drug Administration (FDA).